VETOQUINOL (Veto)

de.marketscreener.com/VETOQUINOL-36676/unternehmen/

Vequinol ist spezialisiert auf die Erforschung, Entwicklung, Herstellung und Vermarktung von Tierarzneimitteln und Produkten für Haustiere (55,7% des Nettoumsatzes; Hunde, Katzen usw.) und Nutztiere (44,3%; Rinder, Schweine, Geflügel usw.). Die Tätigkeit der Gruppe ist in 4 Produktfamilien organisiert:

- antibiotika;

- entzündungshemmer;

- kardiologische und nephrologische Behandlungen;

- sonstiges: Antiparasitika, Impfstoffe und Ernährungsprodukte.

Ende 2018 verfügte der Konzern über 6 Produktionsstätten auf der ganzen Welt.

Die Nettoumsätze verteilen sich wie folgt auf die einzelnen Regionen: Europa (48,9%), Amerika (34,3%) und Asien/Pazifik (16,8%).

www.vetoquinol.com/eng/content/2019-sales-3960-million-76

2019 SALES: €396.0 MILLION (UP 7.6%)


The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.
Sales of Essentials products, the driving force behind Vetoquinol’s strategy, totaled €190.6 million, up 5.1% at constant exchange rates. Essentials products accounted for 48.1% of Group sales in 2019.

Sales of companion animal products (€226.3 million) accounted for 57.1% of total Vetoquinol sales, up 8.4% at constant exchange rates and up 10.4% as reported. Sales of livestock products came to €169.7 million, up 3.2% at constant exchange rates; sales generated by recently acquired Clarion (Brazil) offset the decline in sales of reproduction range.

All Vetoquinol strategic territories posted growth in 2019, with the Americas up 11.3%, Europe up 3.8% and Asia Pacific up 2.0% at constant exchange rates. Growth in the Americas was boosted by Clarion sales in Brazil from April 2019.

Fourth quarter sales amounted to €112.0 million, up 12.2% as reported and up 10.6% at constant exchange rates. Recent acquisitions boosted fourth quarter sales by 4.0% and exchange rate fluctuations also had a 1.6% positive impact.

All strategic territories posted strong fourth quarter growth at constant exchange rates, with Europe up 3.0%, the Americas up 21.6% and Asia Pacific up 7.1%. Fourth quarter sales of Essentials products rose 7.2% at constant exchange rates.

As of December 31, 2019, the financial structure of Vetoquinol remains solid. The year-end results will take into account the impact of the industrial steps initiated during the second semester. The audit of the Group financial statements was in progress at time of release.

Vetoquinol CEO Matthieu Frechin said: “We achieved a solid second semester and our annual performance is the result of our focused strategy and the acquisition in Brazil. This is reflected in the continued growth in Essentials sales across all strategic territories. The integration of Clarion in Brazil is progressing according to plan, while we continue to work on reorganizing our production facilities in Europe. We therefore look forward to 2020 with confidence in our plans to invest and secure sustainable long-term growth for our Group.”

www.vetoquinol.com/eng/content/...ealth-european-union-and-uk

VETOQUINOL TO ACQUIRE RIGHTS FOR PROFENDER® AND DRONTAL® FROM ELANCO ANIMAL HEALTH FOR THE EUROPEAN ECONOMIC AREA AND THE UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. This acquisition will be financed through a combination of available cash and committed financing from Vetoquinol banking partners for $140 million in an all cash deal subject to customary post-closing adjustments. The deal is expected to close by mid-year 2020.
According to the terms of the deal, Vetoquinol will acquire the Profender® and Drontal® product families, the intellectual property, registrations and other rights currently owned by Bayer AG’s animal health business. The Profender® and Drontal® families of products are spot-on and tablet de-wormer products for cats and dogs.

Matthieu Frechin, CEO of Vetoquinol, said "We are very pleased to acquire the Profender® and Drontal® product lines that are highly valued by veterinarians and pet owners. The acquisition of these two strong brands is at the heart of our strategy. On the one hand, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. On the other hand, they will strengthen our portfolio of Essentials, the engine of our growth.

www.vetoquinol.com/eng/content/2021-first-half-results-0
2021 FIRST HALF RESULTS
29/07/2021 | 18:00
STRONG PERFORMANCE ACROSS THE BOARD

First half sales: €255m (up 33.5% at constant exchange rates)
Essentials sales: €143m (up 45.2% at constant exchange rates)
EBIT before depreciation of acquired assets: €57m (22.3% of sales)
Net income - Group share: €36m

www.vetoquinol.com/sites/corporate/files/...iels_2021_eng/18/

de.marketscreener.com/kurs/aktie/...um-30-Juni-2022-41802277/

Vetoquinol SA berichtet über die Ergebnisse für das Halbjahr bis zum 30. Juni 2022
15.09.2022 | 21:20

Vetoquinol SA hat die Ergebnisse für das Halbjahr zum 30. Juni 2022 bekannt gegeben. Für das Halbjahr meldete das Unternehmen einen Umsatz von 270,76 Millionen Euro gegenüber 255,33 Millionen Euro vor einem Jahr. Der Nettogewinn belief sich auf 21,4 Millionen Euro gegenüber 36,19 Millionen Euro vor einem Jahr.

Der unverwässerte Gewinn je Aktie aus dem fortgeführten Geschäft betrug 1,81 EUR gegenüber 3,06 EUR im Vorjahr. Das verwässerte Ergebnis je Aktie aus fortgeführten Geschäftsbereichen betrug 1,83 EUR gegenüber 3,07 EUR im Vorjahr.

www.businesswire.com/news/home/20220923005285/en/

https://www.ariva.de/news/...nol-sales-1st-quarter-2024-134m-11228229

At June 30, 2024, almost all the Group's strategic countries were up from the first half 2023. This is the fruit of the ongoing work of our teams in the field. The Europe strategic territory grew by +5.0% on a reported basis, with the return of volume growth. This is the result of the sustained performance of Essentials products in the Group's first territory. The Asia/Pacific/Rest of World territory grew by 10.0% on a reported basis. The Americas, i.e. Canada, Brazil and Mexico, were also up. In the United States, on the other hand, the expected landing after several years of strong growth was harder than anticipated. This was due to a decline in inventories at American wholesalers, coupled with the temporary unavailability of a product range. These factors had a negative impact of -8.7% on sales in this territory.

Sales of products for companion animals (€188m) were up +3.8% on a reported basis and accounted for 71.2% of the group's total sales (vs. €181m in H1 2023). Farm animals products came to €76 million, up +1.8% on a reported basis (vs. €75 million in H1 2023).

Gross margin on purchases was 72.3%, slightly up on the H1 2023 figure. This trend is linked to the product mix, and in particular to the continued growth of Essential products, as well as to selling price increases of over +3%. These factors offset the rise in purchasing costs for raw materials and outsourced manufacturing.

Other external purchases and expenses rose sharply by +20.8% (vs. -7.9% in H1 2023), i.e. +€10.3m without any significant currency impact, reflecting increased R&D and marketing expenditure (+€9.0m). Personnel costs were up +€4.3m, reflecting salary inflation applied in the Group. Total headcount is up slightly: 2,519 at June 30, 2024 vs. 2,497 at June 30, 2023.

Depreciation and amortization charges linked to IFRS 16 generated a depreciation charge of -3.0 million vs. -2.9 million at June 30, 2023.

EBIT before amortization of intangible assets acquired amounted to €38.5 million for the year ended June 30, 2024, representing 14.6% of total sales.

Group operating income recurring was €32 million (12.1% of sales).

Other operating income and expenses amounted to €1.1m, compared with €2.6m at June 30, 2023. This net income relates to the sale of an industrial site in Brazil. As a reminder, the net income of €2.6 million recorded at June 30, 2023 included a renegotiation of the acquisition price of Clarion (Brazilian subsidiary) and reflected an uncertain local macro-economic situation.

Income tax expense for H1 2024 was -€11.2m (vs. -€10.4m in H1 2023). The apparent tax rate was 32.0% (vs. 24.4% at end June 2023).

Vetoquinol's EBITDA stood at €45 million at June 30, 2024, (17.0% of sales). It has been impacted by the drop in business in the United States, by the increased pace of R&D spending (8.1% of sales vs. 6.9% of sales in H1 2023) to support the Group's development, and by the decision to commit a significant portion of the annual marketing budget in the first half of the year.

Net income for the Vetoquinol Group amounted to €24 million, or 9.0% of H1 2024 sales.

weiter hier:
www.finanznachrichten.de/...ol-2024-half-year-results-004.htm